NRC FORM 591 PAI (10-2011)	NRC FORM 591 PART 1 U.S. NUCLEAR REGULATORY COMMISSION							
10 CFR 2.201 SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION								
1. LICENSEE/LOCATIO	N INSPECTED:		2. NRC/REGIONAL OFFICE					
Christian Hospita		Region III						
Dept. of Nuclear		U. S. Nuclear Regulatory Commission						
11133 Dunn Roa St. Louis, Missou		2443 Warrenville Road, Suite 210						
,		Lisle, IL 60532-4352						
REPORT NUMBER(S		L. HOSHOS MUNDS	7(0)	S. DATE(O) OF INDESTRO	,			
3. DOCKET NUMBER(S 030-02382		4. LICENSE NUMBE 24-13383-01		5. DATE(S) OF INSPECTION 06/26/2013	N			
LICENSEE: The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:								
✓ 1. Based on	the inspection findings, no violations v	vere identified.						
2. Previous	2. Previous violation(s) closed.							
The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.								
	Non-cited violation(s) were discuss	sed involving the fol	lowing requirement(s):					
During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11. (Violations and Corrective Actions)								
					·			
Statement of Corrective Actions I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.								
TITLE	PRINTED NAME		SIGNATURE		DATE			
LICENSEE'S REPRESENTATIVE								
NRC INSPECTOR	Bill C. Lin		Toll	>	7/12/13			
BRANCH CHIEF	Aaron T. McCraw			/	7/15/12			

NRC FORM 591M PART 3				ICLEAR REGULATORY COMMISSION					
10-2011) 10 CFR 2.201 Docket File Information									
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION									
1. LICENSEE/LOCATION INSPECTE	ED:		2. NRC/REGIONAL OFFICE						
Christian Hospital			Desire III						
Dept. of Nuclear Medicine			Region III U. S. Nuclear Regulatory Commission						
11133 Dunn Road			2443 Warrenville Road, Suite 210						
St. Louis, Missouri 63136			Lisle, IL 60532-4352						
REPORT NUMBER(S) 2013-0	Ź								
3. DOCKET NUMBER(S)		4. LICENSE NUMBER(S)		5. DATE(S) OF INSPECTION					
030-02382		24-13383-01		06/26/2013					
6. INSPECTION PROCEDURES USE	D	7. INSPECTION FOCUS AREAS							
87131		3.01-3.08							
SUPPLEMENTAL INSPECTION INFORMATION									
1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTAC	Т	4. TELEPHONE NUMBER					
2120	3	Jerri Robertson,	CNMT	(314) 653-4350					
✓ Main Office Inspection Next Inspection Date: June, 2016 ✓ Field Office Inspection 1225 Graham Road, Florissant, Missouri Temporary Job Site Inspection									
		PROGRAM S	OPF						
The licensee was a community hospital authorized to use licensed material permitted by Title 10 Code of Federal Regulations 35.100, 35.200, 35.300, and 35.400. The hospital is staffed with four full-time nuclear medicine technologist (NMT). The hospital performs approximately 35 diagnostic procedures weekly using Tc-99m from the local nuclear pharmacy in the form of unit doses. Typically in a year, the hospital administered I-131 for approximately 45 treatments of hyperthyroidism and four treatments for thyroid cancer, and 45 whole body CA followup studies. Radioiodine was obtained from a licensed nuclear pharmacy in capsule form. Occasionally, the hospital administered one to two cases of Sm-153 Quadramet infusion for metastatic bone disease. The licensee obtained an outside consultant to perform program audits and training. At the time of the inspection, the licensee's Section 35.400 program was inactive. The licensee had disposed of its Cs-137 source inventory. The licensee had no plan in the near future to restart the Section 35.400 program.									
Performance Observations									
The inspection consisted of tour of the facilities, interviews of licensee personnel, and independent measurements. The inspector tour the main hospital facility, and the new cardiology clinic in Florissant, Missouri. The inspector also reviewed selected records such as dosimetry records, annual audits, radiation training, survey instrument calibrations, package receipt, dose calibrator calibrations, constancy checks, inventory disposal, and Written Directives. The inspection included observations of security of byproduct material, use of personnel monitoring, dose calibrator QA checks, areas surveys, and administration of licensed materials to two patients. The inspector also verified that the licensee's Cs-137 brachytherapy sources were disposed of in accordance with NRC regulatory requirements. The inspector performed an in office review of the licensee's annual radiation safety training program until July 10, 2013. The inspector performed a final telephone exit meeting with the licensee on July 11, 2013. No violations of NRC regulatory requirements were identified.									